Reshaping the gut microbiota: A novel oppinion of Eucommiae cortex polysaccharide alleviate learning and memory impairments in Alzheimer’s disease DOI Creative Commons

Yongkang Zhao,

Wenxing Zhao,

Xuejun Chai

et al.

Journal of Advanced Research, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Alzheimer's disease (AD), which is a chronic neurodegenerative disorder, marked by the progressive deteriorations in learning and memory capabilities. The microbiota-gut-brain axis has come to be regarded as crucial element relation pathogenesis well treatment of AD. Eucommiae cortex polysaccharides (EPs), being among most plentiful substances present cortex, show potential exert immunomodulatory neuroprotective function. However, whether EPs are protective against AD their mechanism action remain investigated OBJECTIVES: We hypothesize that can regulate brain glutamine metabolism through gut microbiota butyric acid metabolized them, improve oxidative stress autophagy brain, thus alleviate In study, we used (0.25 % w/w food) fecal transplantation, butyrate supplementation (0.1 M water), intervene mice. Multi-omics were determine AD-related impairments. Our results suggest EPs, functioning prebiotic, alleviated impairments Mechanistically, able reshape microbiota, promote growth involved short-chain fatty metabolism, particularly butyrate-producing microbes. produced these microbes improves microenvironment modulating mediated glutamate improving mice, inhibiting formation deposition beta-amyloid proteins. Fecal transplantation (FMT) further confirm this conclusion. highlighted with microbiota-dependent manner acid-metabolizing bacteria plays central role regulating microenvironmental homeostasis. Meanwhile, study provides new insights into natural products.

Language: Английский

Targeting immunogenic cell stress and death for cancer therapy DOI
Lorenzo Galluzzi, Emma Guilbaud,

Darby Schmidt

et al.

Nature Reviews Drug Discovery, Journal Year: 2024, Volume and Issue: 23(6), P. 445 - 460

Published: April 15, 2024

Language: Английский

Citations

77
A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation DOI Creative Commons

Ziqi Ma,

Tao Zuo, Norbert Frey

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Sept. 23, 2024

Language: Английский

Citations

19
Fungi, immunosenescence and cancer DOI Creative Commons
Bin Xu,

Zan Luo,

Xing Niu

et al.

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: 109, P. 67 - 82

Published: Jan. 7, 2025

Language: Английский

Citations

4
The role of microbial indole metabolites in tumor DOI Creative Commons
Dingjiacheng Jia, Zheng Kuang, Liangjing Wang

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: Oct. 1, 2024

The gut microbiota can produce a variety of microbial-derived metabolites to influence tumor development. Tryptophan, an essential amino acid in the human body, be converted by microorganisms via indole pathway such as Indole-3-Lactic Acid (ILA), Indole-3-Propionic (IPA), Indole Acetic (IAA) and Indole-3-Aldehyde (IAld). Recent studies have shown that play key roles progression, they used adjuvant regimens for immunotherapy or chemotherapy. Here, we summarize recent findings on common microbial provide review mechanisms different microenvironment. We further discuss limitations current metabolite research future possibilities. It is expected will new strategies clinical therapy.

Language: Английский

Citations

9
Microbiome and lung cancer: carcinogenic mechanisms, early cancer diagnosis, and promising microbial therapies DOI
Weici Liu, Zheshun Pi, Xiaokun Wang

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 196, P. 104322 - 104322

Published: March 7, 2024

Language: Английский

Citations

8
Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy DOI Creative Commons
Jie Liu, Bei Li, Li Li

et al.

Small, Journal Year: 2024, Volume and Issue: unknown

Published: May 21, 2024

Immuno-stimulative effect of chemotherapy (ISECT) is recognized as a potential alternative to conventional immunotherapies, however, the clinical application constrained by its inefficiency. Metronomic chemotherapy, though designed overcome these limitations, offers inconsistent results, with effectiveness varying based on cancer types, stages, and patient-specific factors. In parallel, wealth preclinical nanomaterials holds considerable promise for ISECT improvement modulating cancer-immunity cycle. area biomedical nanomaterials, current literature reviews mainly concentrate specific category nanotechnological perspectives, while two essential issues are still lacking, i.e., comprehensive analysis addressing causes inefficiency thorough summary elaborating improvement. This review thus aims fill gaps catalyze further development in this field. For first time, comprehensively discusses It then meticulously categorizes six types improving ISECT. Subsequently, practical strategies proposed inefficient ISECT, along detailed discussion exemplary nanomedicines. Finally, provides insights into challenges perspectives chemo-immunotherapy innovations nanomaterials.

Language: Английский

Citations

7
Gut microbiota and immunosenescence in cancer DOI

Yaozheng Xu,

Chuan He,

Ying Xi

et al.

Seminars in Cancer Biology, Journal Year: 2024, Volume and Issue: 104-105, P. 32 - 45

Published: Aug. 8, 2024

Language: Английский

Citations

7
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective DOI Creative Commons
Yang Xiao, Yongsheng Li,

Huakan Zhao

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Sept. 18, 2024

Language: Английский

Citations

7
Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential DOI Creative Commons

Mesut Yiğit,

Omer Faruk Basoglu,

Derya Unutmaz

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: March 13, 2024

Mucosal-associated invariant T (MAIT) cells play diverse roles in cancer, infectious diseases, and immunotherapy. This review explores their intricate involvement from early detection to dual functions promoting inflammation mediating anti-tumor responses. Within the solid tumor microenvironment (TME), MAIT can acquire an ‘exhausted’ state secrete tumor-promoting cytokines. On other hand, are highly cytotoxic, there is evidence that they may have immune response. The frequency of subsets has also been shown prognostic value several cancer types. Recent innovative approaches, such as programming with chimeric antigen receptors (CARs), provide a novel exciting approach utilizing these cell-based Because restricted cell receptor (TCR) recognize common antigen, this mitigates potential graft-versus-host disease (GVHD) opens possibility using allogeneic off-the-shelf therapies cancer. Additionally, we outline interactions microbiome critical role diseases how impact responses cells. Understanding complex lead therapeutic strategies harnessing targeting capabilities

Language: Английский

Citations

6
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma DOI Creative Commons

Chengpei Zhu,

Chenchen Zhang, Shanshan Wang

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2024, Volume and Issue: 12(6), P. e008686 - e008686

Published: June 1, 2024

Background The association between gut bacteria and the response to immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC) has been studied; however, multi-kingdom microbiome alterations interactions ICI-treated HCC cohorts are not fully understood. Methods From November 2018 April 2022, patients receiving ICI treatment for advanced were prospectively enrolled. Herein, we investigated microbiota characterization of microbiome, mycobiome, metabolome using metagenomic, ITS2, metabolomic data sets 80 with HCC. Results Our findings demonstrated that metabolites differed significantly durable clinical benefit (DCB) non-durable (NDB) groups, whereas differences smaller fungi. overall diversity fungi before was higher DCB group than NDB group, difference began change use immunotherapy after 6–8 weeks. We also explored microbes established 18 bacterial species models as predictive biomarkers predicting whether is sustained (area under curve=75.63%), screened two ( Actinomyces_sp_ICM47 , Senegalimassilia_anaerobia ) one metabolite (galanthaminone) prognostic survival treated ICI. Conclusions In this study, status microbiota, including bacteria, fungi, their metabolites, described by multiomics sequencing first time demonstrate potential taxa efficacy, biomarkers.

Language: Английский

Citations

6